Emergent BioSolutions(NYSE) EBS

Market Cap$249.73M

Since IPO (2006)-56%

5 Year-92%

1 Year-41%

1 Month-41%

$4.84

-8.85%

-0.47Today

After hours$4.85+$0.01 (+0.21%)

Emergent BioSolutions last closing stock price
Metric	Price	Date
Last close	USD 4.84	2026-08-07

Emergent BioSolutions stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-32.96%	USD 7.22	2026-07-31
1 month	-40.54%	USD 8.14	2026-07-08
3 month	-49.05%	USD 9.50	2026-05-08
Year to date	-60.84%	USD 12.36	2025-12-31
1 year	-41.26%	USD 8.24	2025-08-07
3 year	-32.78%	USD 7.20	2023-08-08
5 year	-92.04%	USD 60.81	2021-08-06
Since inception	-55.79%	USD 10.95	2006-11-15

Emergent BioSolutions Financials at a Glance

Market Cap

$249.73M

Revenue (TTM)

$770.20M

Net Income (TTM)

-$176.80M

EPS (TTM)

-$3.55

P/E Ratio

-1.36

Dividend

$0.00

Beta (Volatility)

1.76 (High)

Dividend

$0.00

Beta (Volatility)

1.76 (High)

Price

$4.84

Volume

3,140,679.267

Open

$5.40

Price

$4.84

Volume

3,140,679.267

Open

$5.40

Previous Close

$4.84

Daily Range

$4.81 - $5.55

52-Week Range

$4.81 - $14.06

Estimated Earnings Date

Nov 11, 2026

Dividend

$0.00

Beta (Volatility)

1.76 (High)

Price

$4.84

Volume

3,140,679.267

Open

$5.40

Previous Close

$4.84

Daily Range

$4.81 - $5.55

52-Week Range

$4.81 - $14.06

Estimated Earnings Date

Nov 11, 2026

EBS News

Page 1

EBS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Emergent BioSolutions

Emergent BioSolutions helps people survive medical emergencies like drug overdoses and dangerous diseases. It makes products for governments and citizens to use during health crises. These solutions protect communities from accidental or intentional harm.

Defending Against Health Threats

MCM Products: Vaccines and treatments for anthrax, smallpox, and Ebola; generated $101.8 million in revenue during Q1 2026.
Naloxone Products: Nasal sprays like NARCAN and KLOXXADO that reverse the effects of opioid overdoses; generated $42.9 million in revenue during Q1 2026.
Bioservices: Contract manufacturing and development support for other pharmaceutical firms and government agencies.
Contracts and Grants: Research and development work funded by external organizations to address emerging public health threats.

Recent Strategic Reshaping

Acquired exclusive rights for KLOXXADO from Hikma Pharmaceuticals Inc. in January 2025.
Sold the travel health business to Bavarian Nordic in May 2023 to focus on core preparedness markets.
Completed the sale of the Baltimore-Bayview manufacturing facility in March 2025.
Entered a new $150 million term loan agreement with OrbiMed Royalty & Credit Opportunities V, LP in April 2026.

A Specialized Infrastructure

The company maintains a specialized infrastructure to support the Strategic National Stockpile, which is a national repository for emergency medical supplies. Its manufacturing network provides molecule-to-market services, covering drug development through final product packaging.

Performance by the Numbers

Total revenue fell to $156.1 million in Q1 2026, a 29.7% decrease from $222.2 million in Q1 2025.
Net income reached $6.8 million in Q1 2026, down 90% from $68 million in the prior year.
Income from operations hit $10.5 million in Q1 2026, compared to $49.9 million in Q1 2025.
Cash and equivalents totaled $160.3 million as of March 31, 2026.

Bottom Line

Emergent has simplified its operations by selling non-core assets and focusing on emergency response products. This restructuring strategy aims to stabilize the company following a significant decline in quarterly revenue and profit.

AI Generated • May 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

900

CEO

Joseph C. Papa, MBA

Website

www.emergentbiosolutions.com

Headquarters

Gaithersburg, MD 20879, US

EBS Financials

Key Financial Metrics (TTM)

Gross Margin

49.40%

Operating Margin

-7.06%

Net Income Margin

-22.96%

Return on Equity

-35.91%

Return on Capital

10.07%

Return on Assets

-15.83%

Earnings Yield

-73.53%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$249.73M

Shares Outstanding

51.60M

Volume

3.14M

Avg. Volume

896.93K

Financials (TTM)

Gross Profit

$380.50M

Operating Income

-$54.40M

EBITDA

-$23.70M

Operating Cash Flow

$25.40M

Capital Expenditure

-$11.80M

Free Cash Flow

$13.60M

Cash & ST Invst.

$139.70M

Total Debt

$581.80M

Emergent BioSolutions Performance Analysis

Emergent BioSolutions annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 1,117,500,000	-37.0%
2023	2023-12-31	USD 1,049,300,000	-6.1%
2024	2024-12-31	USD 1,043,600,000	-0.5%
2025	2025-12-31	USD 742,900,000	-28.8%

Emergent BioSolutions sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	64.0%
Q4	2025-12-31	-35.7%
Q1	2026-03-31	5.0%
Q2	2026-06-30	50.1%

Emergent BioSolutions annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -4.22	N/A
2023	2023-12-31	USD -14.85	251.7%
2024	2024-12-31	USD -3.60	-75.8%
2025	2025-12-31	USD 0.93	N/A

Emergent BioSolutions sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	513.6%
Q4	2025-12-31	-214.3%
Q1	2026-03-31	107.1%
Q2	2026-06-30	-4797.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$234.30M

+66.3%

Gross Profit

$137.20M

+138.6%

Gross Margin

58.56%

N/A

Market Cap

$249.73M

N/A

Market Cap/Employee

$277.47K

N/A

Employees

900

N/A

Net Income

-$180.20M

-1401.7%

EBITDA

-$156.30M

-813.7%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$139.70M

-48.5%

Total Debt

$581.80M

-13.9%

Accounts Receivable

$190.00M

+138.1%

Inventory

$303.60M

-10.3%

Long Term Debt

$581.80M

-13.7%

Short Term Debt

$0.00

-100.0%

Return on Assets

-15.83%

N/A

Return on Invested Capital

-5.47%

N/A

Free Cash Flow

-$18.30M

-117.7%

Operating Cash Flow

-$16.20M

-115.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ORGOOrganogenesis Holdings Inc.

ORGOOrganogenesis Holdings Inc.$1.86-22.82%

SIGASIGA Technologies, Inc.

SIGASIGA Technologies, Inc.$3.05-2.24%

SNDLSNDL Inc.

SNDLSNDL Inc.$1.23+2.50%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$8.76+2.10%

AQSTAquestive Therapeutics, Inc.

AQSTAquestive Therapeutics, Inc.$3.94+0.51%

ESPREsperion Therapeutics, Inc.

ESPREsperion Therapeutics, Inc.$3.18+0.00%

RIGLRigel Pharmaceuticals, Inc.

RIGLRigel Pharmaceuticals, Inc.$40.17+2.42%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$133.11+0.16%

TTDThe Trade Desk

TTDThe Trade Desk$13.80-0.22%

NVDANvidia

NVDANvidia$223.96+0.02%

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF$82.76+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.11+0.06%

PLTRPalantir Technologies

PLTRPalantir Technologies$172.01+0.10%

INTCIntel

INTCIntel$101.65+0.02%

Questions About EBS

What is the current price of Emergent BioSolutions?

Emergent BioSolutions is trading at $4.84 per share.

What is the 52-week range for Emergent BioSolutions?

Over the past 52 weeks, Emergent BioSolutions has traded between $4.81 and $14.06.

How much debt does Emergent BioSolutions have?

As of the most recent reporting period, Emergent BioSolutions reported total debt of $588.20M.

How much cash does Emergent BioSolutions have on hand?

Emergent BioSolutions reported $140.90M in cash and cash equivalents in its most recent financial results.

What is Emergent BioSolutions’s dividend yield?

Emergent BioSolutions does not currently have a dividend yield.

Emergent BioSolutions(NYSE) EBS

Emergent BioSolutions Financials at a Glance

EBS News

6 Best Vaccine Stocks for 2026 and How to Invest

Why Emergent BioSolutions Stock Blasted Higher Today

Why Emergent BioSciences Stock Plummeted Today

Why Emergent BioSolutions Stock Is Skyrocketing Today

Why Emergent BioSolutions Stock Is Tumbling Today

Why Emergent BioSolutions Stock Dived by 9% Today

Better Recovery-Story Buy: Emergent BioSolutions or Invitae?

Is Emergent BioSolutions Stock a Buy Now?

EBS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Emergent BioSolutions

Defending Against Health Threats

Recent Strategic Reshaping

A Specialized Infrastructure

Performance by the Numbers

Bottom Line

EBS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Emergent BioSolutions Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About EBS

What is the current price of Emergent BioSolutions?

What is the 52-week range for Emergent BioSolutions?

How much debt does Emergent BioSolutions have?

How much cash does Emergent BioSolutions have on hand?

What is Emergent BioSolutions’s dividend yield?

Premium Investing Services